Product Information
TIZANIDINE HCL 2 MG TABLET is a generic product labeled by Rising Pharma Holdings Inc., priced at $0.0317 per EA under NDC 64980065810. Its NADAC has been published 53 times since Oct 1, 2025.
FDA first approved this application on Aug 7, 2024. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
2 mg/1
Manufacturer
Rising Pharma Holdings Inc.NDC
64980065810
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
TIZANIDINE HYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA218920FDA Approved
8/7/2024
TE Code
AB
On Market Since
12/15/2024
Pharmacological Classes
Price Statistics
The NADAC for TIZANIDINE HCL 2 MG TABLET has been published 53 times since Oct 1, 2025, and over the history we have for it it has declined 17.8%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.0317 per EA |
|---|---|
| All-time high | $0.0386 (Oct 15, 2025) |
| All-time low | $0.0299 (Jul 22, 2026) |
| 52-week high | $0.0386 |
| 52-week low | $0.0299 |
| Median price | $0.0309 |
| Average price | $0.0320 |
| Largest weekly change | -7.6% (Nov 19, 2025) |
| Weeks tracked | 53 |
| Tracking since | Oct 1, 2025 |
Generic Alternatives
The matcher finds 3 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Rising Pharma Holdings Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
tizanidine market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Central alpha-2 Adrenergic Agonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of TIZANIDINE HCL 2 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for TIZANIDINE HCL 2 MG TABLET, manufactured by Rising Pharma Holdings Inc., is $0.0317 per EA (NDC 64980065810), effective Sep 30, 2026.
How has the price of TIZANIDINE HCL 2 MG TABLET changed over time?
Over the history we have for it, the NADAC for TIZANIDINE HCL 2 MG TABLET has declined 17.8%. It has been tracked across 53 weekly CMS publications since Oct 1, 2025.
What are the highest and lowest recorded NADAC prices for TIZANIDINE HCL 2 MG TABLET?
Since Oct 1, 2025, the NADAC for TIZANIDINE HCL 2 MG TABLET has ranged from a low of $0.0299 (Jul 22, 2026) to a high of $0.0386 (Oct 15, 2025), with a median of $0.0309 per EA.
Are there cheaper alternatives to TIZANIDINE HCL 2 MG TABLET?
3 manufacturers publish a NADAC-priced product with the same active ingredient and strength as TIZANIDINE HCL 2 MG TABLET in a comparable dosage form, but none are currently priced below it.
Who manufactures TIZANIDINE HCL 2 MG TABLET?
TIZANIDINE HCL 2 MG TABLET (NDC 64980065810) is labeled by Rising Pharma Holdings Inc., and CMS classifies it as a generic product.